An update on clinical proteomics in Alzheimer's research

Journal of Neurochemistry

Volumn 112, Issue 6, 2010, Pages 1386-1414

  Korolainen, Minna A ^a,b,c   Nyman, Tuula A ^c   Aittokallio, Tero ^d   Pirttilä, Tuula ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Alzheimer's disease; Blood; Brain; CSF; Proteomics; Two dimensional gel electrophoresis

Indexed keywords

ACONITATE HYDRATASE; ADENYLATE KINASE; ALCOHOL DEHYDROGENASE; ALPHA CRYSTALLIN; ALPHA ENOLASE; ALPHA INTERNEXIN; BETA ACTIN; BETA SYNUCLEIN; BRAIN PROTEIN; CALPAIN 2; CARBONATE DEHYDRATASE II; CARBONYL REDUCTASE; CREATINE KINASE BB; CYTOCHROME C OXIDASE; DIAZEPAM BINDING INHIBITOR; ELONGATION FACTOR TU; ENOLASE; FASCIN; FATTY ACID BINDING PROTEIN; FRUCTOSE BISPHOSPHATE ALDOLASE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE REGULATED PROTEIN; GLUCOSE REGULATED PROTEIN 94; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DEHYDROGENASE; GLUTATHIONE TRANSFERASE M3; GUANINE DEAMINASE; HEAT SHOCK PROTEIN 60; PROTEOME; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ALZHEIMER DISEASE; HUMAN; NEUROPATHOLOGY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNINDEXED SEQUENCE;

ALZHEIMER DISEASE; ANIMALS; BIOMEDICAL RESEARCH; BRAIN; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; PROTEOMICS;

EID: 77249179997     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06558.x     Document Type: Review

References (208)

1. Abdi F., Quinn J. F., Jankovic J. et al. (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9, 293 348.
2. Ai K. Z., Vermuyten K., De Deyn P. P. et al. (1989) A serum protein involved in aging? Mol. Chem. Neuropathol. 11, 131 141.
3. Aksenov M. Y., Aksenova M. V., Butterfield D. A. et al. (2001) Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373 383.
4. Alafuzoff I., Adolfsson R., Bucht G. et al. (1986) Isoelectric focusing and two-dimensional gel electrophoresis in plasma and cerebrospinal fluid from patients with dementia. Eur. Neurol. 25, 285 289.
5. Andlin-Sobocki P., Jönsson B., Wittchen H. U. et al. (2005) Cost of disorders of the brain in Europe. Eur. J. Neurol. 12, 1 27.
6. Balastik M., Lim J., Pastorino L. et al. (2007) Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism? Biochim. Biophys. Acta 1772, 422 429.
7. Balcz B., Kirchner L., Cairns N. et al. (2001) Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 61, 193 201.
8. Bertram L. Tanzi R. E. (2005) The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 115, 1449 1457.
9. Bezprozvanny I. Mattson M. P. (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 31, 454 463.
10. Bharadwaj P. R., Dubey A. K., Masters C. L. et al. (2009) Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J. Cell Mol. Med. 13, 412 421.
11. Blass J. P. Zemcov A. (1984) Alzheimer's disease. A metabolic systems degeneration? Neurochem. Pathol. 2, 103 114.
12. Blennow K. Hampel H. (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2, 605 613.
13. Braak H. Braak E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) 82, 239 259.
14. Burbaeva G. (1992) Physiologically active brain proteins as possible markers of mental diseases. Vestn. Ross. Akad. Med. Nauk 7, 51 54.
15. Burdick D., Soreghan B., Kwon M. et al. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J. Biol. Chem. 267, 546 554.
16. Bush A. I. (2003) The metallobiology of Alzheimer's disease. Trends Neurosci. 26, 207 214.
17. Butterfield D. A. Lange M. L. (2009) Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J. Neurochem. 111, 915 933.
18. Butterfield D. A. Sultana R. (2007) Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 12, 61 72.
19. Butterfield D. A., Gnjec A., Poon H. F. et al. (2006a) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 10, 391 397.
20. Butterfield D. A., Poon H. F., St Clair D. et al. (2006b) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol. Dis. 22, 223 232.
21. Butterfield D. A., Abdul H. M., Opii W. et al. (2006c) Pin1 in Alzheimer's disease. J. Neurochem. 98, 1697 1706.
22. Carmona-Saez P., Chagoyen M., Tirado F. et al. (2007) GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 8, R3.
23. Carrette O., Demalte I., Scherl A. et al. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486 1494.
24. Castano E. M., Roher A. E., Esh C. L. et al. (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 28, 155 163.
25. Castegna A., Aksenov M., Thongboonkerd V. et al. (2002a) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 82, 1524 1532.
26. Castegna A., Aksenov M., Aksenova M. et al. (2002b) Proteomic identification of oxidatively modified proteins in alzheimer's disease brain. part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33, 562.
27. Castegna A., Thongboonkerd V., Klein J. B. et al. (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85, 1394 1401.
28. Cheon M. S., Fountoulakis M., Cairns N. J. et al. (2001) Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 61, 281 288. (Pubitemid 38085090)
29. Cheon M. S., Kim S. H., Fountoulakis M. et al. (2003) Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 61, 225 234.
30. Choe L. H., Dutt M. J., Relkin N. et al. (2002) Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 23, 2247 2251.
31. Choe L., D'Ascenzo M., Relkin N. R. et al. (2007) 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 7, 3651 3660.
32. Choi J., Malakowsky C. A., Talent J. M. et al. (2002) Identification of oxidized plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 293, 1566 1570.
33. Choi J., Levey A. I., Weintraub S. T. et al. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279, 13256 13264.
34. Choi J., Rees H. D., Weintraub S. T. et al. (2005) Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J. Biol. Chem. 280, 11648 11655.
35. Choi J., Sullards M. C., Olzmann J. A. et al. (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 281, 10816 10824.
36. Chong M. S. Sahadevan S. (2005) Preclinical Alzheimer's disease: diagnosis and prediction of progression. Lancet Neurol. 4, 576 579.
37. Cole A. R., Noble W., van Aalten L. et al. (2007) Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J. Neurochem. 103, 1132 1144.
38. Comings D. E. (1982a) Two-dimensional gel electrophoresis of human brain proteins. IV Disorders of glial proliferation and a polymorphism of glial fibrillary acidic protein-GFAP Duarte. Clin. Chem. 28, 805 812.
39. Comings D. E. (1982b) Two-dimensional gel electrophoresis of human brain proteins. III Genetic and non-genetic variations in 145 brains. Clin. Chem. 28, 798 804.
40. Comings D. E. (1982c) Two-dimensional gel electrophoresis of human brain proteins. I Technique and nomenclature of proteins. Clin. Chem. 28, 782 789.
41. Connell C. M., Janevic M. R. Gallant M. P. (2001) The costs of caring: impact of dementia on family caregivers. J. Geriatr. Psychiatry Neurol. 14, 179 187.
42. Crecelius A., Gotz A., Arzberger T. et al. (2008) Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-D DIGE. Proteomics 8, 1276 1291.
43. Cutillas P. R. Vanhaesebroeck B. (2007) Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol. Cell Proteomics 6, 1560 1573.
44. Davidsson P., Westman-Brinkmalm A., Nilsson C. L. et al. (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13, 611 615.
45. DeKosky S. T. Marek K. (2003) Looking backward to move forward: early detection of neurodegenerative disorders. Science 302, 830 834.
46. Desai P. P., Ikonomovic M. D., Abrahamson E. E. et al. (2005) Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex. Neurobiol. Dis. 20, 574 582.
47. Desrosiers R. R., Bertrand Y., Nguyen Q. T. et al. (2003) Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease. Biochem. J. 374, 463 471.
48. Dubois B., Feldman H. H., Jacova C. et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734 746.
49. Edgar P. F., Schonberger S. J., Dean B. et al. (1999) A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals. Mol. Psychiatry 4, 173 178.
50. Ferrer I., Martinez A., Boluda S. et al. (2008) Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 9, 181 194.
51. Ferri C. P., Prince M., Brayne C. et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112 2117.
52. Finehout E. J., Franck Z., Choe L. H. et al. (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 61, 120 129.
53. Finehout E. J., Franck Z. Lee K. H. (2005) Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers 21, 93 101.
54. Fountoulakis M. Kossida S. (2006) Proteomics-driven progress in neurodegeneration research. Electrophoresis 27, 1556 1573.
55. Fountoulakis M., Cairns N. Lubec G. (1999) Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome. J. Neural Transm. Suppl. 57, 323 335.
56. Fountoulakis M., Hardmeier R., Hoger H. et al. (2001) Postmortem changes in the level of brain proteins. Exp. Neurol. 167, 86 94.
57. Frankfort S. V., van Campen J. P., Tulner L. R. et al. (2008) Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS). Curr. Clin. Pharmacol. 3, 144 154.
58. Franzen B., Yang Y., Sunnemark D. et al. (2003) Dihydropyrimidinase related protein-2 as a biomarker for temperature and time dependent post mortem changes in the mouse brain proteome. Proteomics 3, 1920 1929.
59. Frey H. J., Mattila K. M., Korolainen M. A. et al. (2005) Problems associated with biological markers of Alzheimer's disease. Neurochem. Res. 30, 1501 1510.
60. Gao J., Ade A. S., Tarcea V. G. et al. (2009) Integrating and annotating the interactome using the MiMI plugin for cytoscape. Bioinformatics 25, 137 138.
61. Garbis S., Lubec G. Fountoulakis M. (2005) Limitations of current proteomics technologies. J. Chromatogr. A 1077, 1 18.
62. Giacobini E. Becker R. E. (2007) One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? J. Alzheimers Dis. 12, 37 52.
63. Gibson F., Anderson L., Babnigg G. et al. (2008) Guidelines for reporting the use of gel electrophoresis in proteomics. Nat. Biotechnol. 26, 863 864.
64. Golde T. E. (2003) Alzheimer disease therapy: can the amyloid cascade be halted? J. Clin. Invest. 111, 11 18.
65. Goldknopf I. L. (2008) Blood-based proteomics for personalized medicine: examples from neurodegenerative disease. Expert. Rev. Proteomics 5, 1 8.
66. Goldstein L. E., Muffat J. A., Cherny R. A. et al. (2003) Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 361, 1258 1265.
67. Greber S., Lubec G., Cairns N. et al. (1999) Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Electrophoresis 20, 928 934. (Pubitemid 29222451)
68. Grundke-Iqbal I., Iqbal K., Tung Y. C. et al. (1986a) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913 4917.
69. Grundke-Iqbal I., Iqbal K., Quinlan M. et al. (1986b) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084 6089.
70. Gygi S. P., Rist B., Gerber S. A. et al. (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994 999.
71. Hamidi Asl K., Liepnieks J. J., Nakamura M. et al. (1999) Organ-specific (localized) synthesis of Ig light chain amyloid. J. Immunol. 162, 5556 5560.
72. Hansson S. F., Andreasson U., Wall M. et al. (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J. Alzheimers Dis. 16, 389 397.
73. Hardy J. Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353 356.
74. Harrington M. G. Merril C. R. (1984) Two-dimensional electrophoresis and "ultrasensitive" silver staining of cerebrospinal fluid proteins in neurological diseases. Clin. Chem. 30, 1933 1937.
75. Harrington M. G., Merril C. R. Torrey E. F. (1985) Differences in cerebrospinal fluid proteins between patients with schizophrenia and normal persons. Clin. Chem. 31, 722 726.
76. Harrington M. G., Merril C. R., Asher D. M. et al. (1986) Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N. Engl. J. Med. 315, 279 283.
77. Heneka M. T. O'Banion M. K. (2007) Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 184, 69 91.
78. Hernandez F., Gomez de Barreda E., Fuster-Matanzo A. et al. (2009) GSK3: a possible link between beta amyloid peptide and tau protein. Exp. Neurol. doi :.
79. Herukka S. K., Hallikainen M., Soininen H. et al. (2005) CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64, 1294 1297.
80. Hesse C., Nilsson C. L., Blennow K. et al. (2001) Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization- time of flight-mass spectrometry. Electrophoresis 22, 1834 1837.
81. Hilbig H., Bidmon H. J., Oppermann O. T. et al. (2004) Influence of post-mortem delay and storage temperature on the immunohistochemical detection of antigens in the CNS of mice. Exp. Toxicol. Pathol. 56, 159 171.
82. Hooper C., Killick R. Lovestone S. (2008) The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104, 1433 1439.
83. Hu Y., Malone J. P., Fagan A. M. et al. (2005) Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol. Cell Proteomics 4, 2000 2009.
84. Hutchens T. W. Yip T. T. (1993) New desorption strategies for the mass-spectrometric analysis of macromolecules. Rapid. Com. Mass Spectr. 7, 576 580.
85. Hye A., Lynham S., Thambisetty M. et al. (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042 3050.
86. Hynd M. R., Lewohl J. M., Scott H. L. et al. (2003) Biochemical and molecular studies using human autopsy brain tissue. J. Neurochem. 85, 543 562.
87. Irie K., Murakami K., Masuda Y. et al. (2005) Structure of beta-amyloid fibrils and its relevance to their neurotoxicity: implications for the pathogenesis of Alzheimer's disease. J. Biosci. Bioeng. 99, 437 447.
88. Jabbour W., Pouplard-Barthelaix A., Houlgatte R. et al. (1992) Abnormal expression of actin in lymphocytes of Alzheimer's disease and Down's syndrome patients. J. Neuroimmunol. 38, 199 208.
89. Jayapandian M., Chapman A., Tarcea V. G. et al. (2007) Michigan Molecular Interactions (MiMI): putting the jigsaw puzzle together. Nucleic Acids Res. 35, D566 D571.
90. Johnson G., Gotlib J., Haroutunian V. et al. (1992) Increased phosphorylation of elongation factor 2 in Alzheimer's disease. Brain Res. Mol. Brain Res. 15, 319 326.
91. Jönsson L. Berr C. (2005) Cost of dementia in Europe. Eur. J. Neurol. 12, 50 53.
92. Jung S. M., Lee K., Lee J. W. et al. (2008) Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: Candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Neurosci. Lett. 436, 153 157.
93. Kanninen K., Goldsteins G., Auriola S. et al. (2004) Glycosylation changes in Alzheimer's disease as revealed by a proteomic approach. Neurosci. Lett. 367, 235 240.
94. Keller J. N. (2006) Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Res. Rev. 5, 1 13.
95. Kiehntopf M., Siegmund R. Deufel T. (2007) Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin. Chem. Lab. Med. 45, 1435 1449.
96. Kim S. H., Vlkolinsky R., Cairns N. et al. (2000) Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell. Mol. Life Sci. 57, 1810 1816.
97. Kim S. H., Fountoulakis M., Cairns N. et al. (2001a) Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J. Neural Transm. Suppl. 61, 223 235. (Pubitemid 38085085)
98. Kim S. H., Cairns N., Fountoulakis M. et al. (2001b) Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. Neurosci. Lett. 300, 41 44.
99. Kim S. H., Vlkolinsky R., Cairns N. et al. (2001c) The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci. 68, 2741 2750.
100. Kim S. H., Fountoulakis M., Cairns N. J. et al. (2002) Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochem. Biophys. Res. Commun. 296, 970 975.
101. Klein W. L. (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345 352.
102. Korolainen M. A. Pirttilä T. (2009) Cerebrospinal fluid, serum and plasma protein oxidation in Alzheimer's disease. Acta Neurol. Scand. 119, 32 38.
103. Korolainen M. A., Auriola S., Nyman T. A. et al. (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol. Dis. 20, 858 870.
104. Korolainen M. A., Goldsteins G., Nyman T. A. et al. (2006) Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol. Aging 27, 42 53.
105. Korolainen M. A., Nyman T. A., Nyyssönen P. et al. (2007) Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin. Chem. 53, 657 665.
106. Kosik K. S., Joachim C. L. Selkoe D. J. (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA 83, 4044 4048.
107. Krapfenbauer K., Engidawork E., Cairns N. et al. (2003) Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 967, 152 160.
108. Lee H. G., Perry G., Moreira P. I. et al. (2005) Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol. Med. 11, 164 169.
109. Lewczuk P., Esselmann H., Meyer M. et al. (2003) The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun. Mass Spectrom. 17, 1291 1296.
110. Lewczuk P., Esselmann H., Groemer T. W. et al. (2004) Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol. Psychiatry 55, 524 530.
111. Lewis D. A. (2002) The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology 26, 143 154.
112. Liao L., Cheng D., Wang J. et al. (2004) Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J. Biol. Chem. 279, 37061 37068.
113. Liu H. C., Hu C. J., Chang J. G. et al. (2006) Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 21, 155 161.
114. Lovestone S., Guntert A., Hye A. et al. (2007) Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. Expert Rev. Proteomics 4, 227 238.
115. Maddalena A. S., Papassotiropoulos A., Gonzalez-Agosti C. et al. (2004) Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegener. Dis. 1, 231 235.
116. Mariani E., Polidori M. C., Cherubini A. et al. (2005) Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 827, 65 75.
117. Mattila K. M. Frey H. (1994) Alzheimer brain proteins investigated by two-dimensional gel electrophoresis with immobilized pH gradients in the first dimension. Electrophoresis 15, 721 725.
118. Mattila K. M. Frey H. (1995) Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. Appl. Theor. Electrophor. 4, 189 196.
119. Mattila K. M., Pirttilä T., Blennow K. et al. (1994) Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol. Scand. 89, 192 198.
120. Mazanetz M. P. Fischer P. M. (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 6, 464 479.
121. Mazzola J. L. Sirover M. A. (2002) Alteration of intracellular structure and function of glyceraldehyde-3-phosphate dehydrogenase: a common phenotype of neurodegenerative disorders? Neurotoxicology 23, 603 609.
122. McKhann G., Drachman D., Folstein M. et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939 944.
123. Mhyre T. R., Loy R., Tariot P. N. et al. (2008) Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol. Aging 29, 1631 1643.
124. Mosconi L., Pupi A. De Leon M. J. (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann. N Y Acad. Sci. 1147, 180 195.
125. Muller T., Jung K., Ullrich A. et al. (2008) Disease state, age, sex, and post-mortem time-dependent expression of proteins in AD vs. control frontal cortex brain samples. Curr. Alzheimer Res. 5, 562 571.
126. Nagy Z., Esiri M. M., Jobst K. A. et al. (1995) Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 6, 21 31.
127. Nakamura A. Goto S. (1996) Analysis of protein carbonyls with 2,4-dinitrophenyl hydrazine and its antibodies by immunoblot in two-dimensional gel electrophoresis. J. Biochem. (Tokyo) 119, 768 774.
128. Neve R. L. Robakis N. K. (1998) Alzheimer's disease: a re-examination of the amyloid hypothesis. Trends Neurosci. 21, 15 19.
129. Newman S. F., Sultana R., Perluigi M. et al. (2007) An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J. Neurosci. Res. 85, 1506 1514.
130. Nilsberth C., Westlind-Danielsson A., Eckman C. B. et al. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4, 887 893.
131. Nunan J. Small D. H. (2000) Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett. 483, 6 10.
132. Ojala J., Alafuzoff I., Herukka S. K. et al. (2009) Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol. Aging 30, 198 209.
133. Old W. M., Meyer-Arendt K., Aveline-Wolf L. et al. (2005) Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol. Cell Proteomics 4, 1487 1502.
134. Olsson A., Vanderstichele H., Andreasen N. et al. (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336 345.
135. Ong S. E., Blagoev B., Kratchmarova I. et al. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell Proteomics 1, 376 386.
136. Owen J. B., Di Domenico F., Sultana R. et al. (2009) Proteomics- determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J. Proteome Res. 8, 471 482.
137. Pamplona R., Dalfo E., Ayala V. et al. (2005) Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J. Biol. Chem. 280, 21522 21530.
138. Pan S., Rush J., Peskind E. R. et al. (2008) Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J. Proteome Res. 7, 720 730.
139. Paschen W. (2000) Role of calcium in neuronal cell injury: which subcellular compartment is involved? Brain Res. Bull. 53, 409 413.
140. Pereira C., Agostinho P., Moreira P. I. et al. (2005) Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr. Drug Targets CNS Neurol. Disord. 4, 383 403.
141. Perluigi M., Sultana R., Cenini G. et al. (2009) Redox proteomics identification of HNE-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin. Appl. 3, 682 693.
142. Portelius E., Zetterberg H., Gobom J. et al. (2008) Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. Expert Rev. Proteomics 5, 225 237.
143. Pratico D. (2008) Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann. N Y Acad. Sci. 1147, 70 78.
144. Price J. L. Morris J. C. (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45, 358 368.
145. Puchades M., Hansson S. F., Nilsson C. L. et al. (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 118, 140 146.
146. Qin W., Ho L., Wang J. et al. (2009) S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS ONE 4, e4183.
147. Raber J., Huang Y. Ashford J. W. (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25, 641 650.
148. Ray S., Britschgi M., Herbert C. et al. (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13, 1359 1362.
149. Reddy P. H. McWeeney S. (2005) Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol. Aging 9, 9.
150. Reed T. T., Perluigi M., Sultana R. et al. (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30, 107 120.
151. Reed T. T., Pierce W. M., Markesbery W. R. et al. (2009) Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res. 1274, 66 76.
152. Riederer I. M., Schiffrin M., Kövari E. et al. (2009) Ubiquitination and cystein nitrosylation during aging and Alzheimer's disease. Brain Res. Bull. doi :.
153. Righetti P. G., Castagna A., Antonucci F. et al. (2005) Proteome analysis in the clinical chemistry laboratory: myth or reality? Clin. Chim. Acta 357, 123 139.
154. Roher A. E., Maarouf C. L., Sue L. I. et al. (2009) Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 14, 493 501.
155. Ross P. L., Huang Y. N., Marchese J. N. et al. (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics 3, 1154 1169.
156. Ryberg H. Bowser R. (2008) Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev. Proteomics 5, 249 262.
157. Salloway S., Mintzer J., Weiner M. F. et al. (2008) Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 4, 65 79.
158. Schneider J. A., Arvanitakis Z., Bang W. et al. (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197 2204.
159. Schonberger S. J., Edgar P. F., Kydd R. et al. (2001) Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics 1, 1519 1528.
160. Schroder R. Linke R. P. (1999) Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenic pattern. Virchows Arch. 434, 551 560.
161. Scott R. B. (1993) Extraneuronal manifestations of Alzheimer's disease. J. Am. Geriatr. Soc. 41, 268 276.
162. Sergeant N., David J. P., Lefranc D. et al. (1997) Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. FEBS Lett. 412, 578 582.
163. Setsuie R. Wada K. (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem. Int. 51, 105 111.
164. Shannon P., Markiel A., Ozier O. et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498 2504.
165. Shi M., Caudle W. M. Zhang J. (2009) Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol. Dis. 35, 157 164.
166. Shiozaki A., Tsuji T., Kohno R. et al. (2004) Proteome analysis of brain proteins in Alzheimer's disease: subproteomics following sequentially extracted protein preparation. J. Alzheimers Dis. 6, 257 268.
167. Siesjö B. K. (1984) Cell damage in the brain: a speculative synthesis. Acta Psychiatr. Scand. Suppl. 313, 57 91.
168. Sihlbom C., Davicsson P., Sjögren M. et al. (2008) Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healhy individuals. Neurochem. Res. 33, 1332 1340.
169. Simonsen A. H., McGuire J., Podust V. N. et al. (2007a) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement.Geriatr. Cogn. Disord. 24, 434 440.
170. Simonsen A. H., McGuire J., Hansson O. et al. (2007b) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 64, 366 370.
171. Simonsen A. H., McGuire J., Podust V. N. et al. (2008) Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol. Aging 29, 961 968.
172. Smirnov A. V., Shevtsov P. N. Burbaeva G. (1991) Two-dimensional electrophoretic analysis of the protein spectrum of human brain structures in schizophrenia and senile dementia of the Alzheimer type. Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova 91, 34 36.
173. Song F., Poljak A., Smythe G. A. et al. (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res. Rev. 61, 69 80.
174. Streit W. J., Miller K. R., Lopes K. O. et al. (2008) Microglial degeneration in the aging brain-bad news for neurons? Front. Biosci. 13, 3423 3438.
175. Suh Y. H. Checler F. (2002) Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 54, 469 525.
176. Sultana R. Butterfield D. A. (2009) Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J. Bioenerg. Biomembr. doi :.
177. Sultana R., Boyd-Kimball D., Poon H. F. et al. (2005) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging 3, 3.
178. Sultana R., Poon H. F., Cai J. et al. (2006a) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22, 76 87.
179. Sultana R., Boyd-Kimball D., Poon H. F. et al. (2006b) Redox proteomics
180. Sultana R., Boyd-Kimball D., Poon H. F. et al. (2006c) Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol. Aging 27, 918 925.
181. Sultana R., Reed T., Perluigi M. et al. (2007a) Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J. Cell Mol. Med. 11, 839 851. (Pubitemid 47313301)
182. Sultana R., Boyd-Kimball D., Cai J. et al. (2007b) Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis. 11, 153 164.
183. Sultana R., Perluigi M., Newman S. F. et al. (2009) Redox proteomic analysis of carbonylated proteins in mild cognitive impairment, Antioxid. Redox Signal. doi :.
184. Takuma K., Baba A. Matsuda T. (2004) Astrocyte apoptosis: implications for neuroprotection. Prog. Neurobiol. 72, 111 127.
185. Taylor C. F., Paton N. W., Lilley K. S. et al. (2007) The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol. 25, 887 893.
186. Terry R. D., Masliah E., Salmon D. P. et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572 580.
187. Thambisetty M., Hye A., Foy C. et al. (2008) Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J. Neurol. 255, 1712 1720.
188. Thompson P. W. Lockhart A. (2009) Monitoring the amyloid beta-peptide in vivo-caveat emptor. Drug Discov. Today 14, 241 251.
189. Tomic J. L., Pensalfini A., Head E. et al. (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 35, 352 358.
190. Townsend L. E., Gilroy J., LeWitt P. et al. (1987) Comparison of methods for analysis of CSF proteins in patients with Alzheimer's disease. Neurochem. Pathol. 6, 213 229.
191. Tsuji T., Shiozaki A., Kohno R. et al. (2002) Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem. Res. 27, 1245 1253.
192. Ueno I., Sakai T., Yamaoka M. et al. (2000) Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection. Electrophoresis 21, 1832 1845.
193. Unlü M., Morgan M. E. Minden J. S. (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18, 2071 2077.
194. Vercauteren F. G., Bergeron J. J., Vandesande F. et al. (2004) Proteomic approaches in brain research and neuropharmacology. Eur. J. Pharmacol. 500, 385 398.
195. Vlkolinsky R., Cairns N., Fountoulakis M. et al. (2001) Decreased brain levels of 2′,3′-cyclic nucleotide-3′-phosphodiesterase in Down syndrome and Alzheimer's disease. Neurobiol. Aging 22, 547 553. (Pubitemid 32607738)
196. Wang Q., Woltjer R. L., Cimino P. J. et al. (2005) Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J. 19, 869 871.
197. Wilhelmus M. M., Otte-Holler I., Wesseling P. et al. (2006) Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. Neuropathol. Appl. Neurobiol. 32, 119 130.
198. Wilkins M. R., Arthur J. W., Junius F. K. et al. (2008) Information management for proteomics: a perspective. Expert Rev. Proteomics 5, 663 678.
199. Yoo B. C., Fountoulakis M., Cairns N. et al. (2001a) Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 22, 172 179.
200. Yoo B. C., Cairns N., Fountoulakis M. et al. (2001b) Synaptosomal proteins, beta-soluble N-ethylmaleimide-sensitive factor attachment protein (beta-SNAP), gamma-SNAP and synaptotagmin I in brain of patients with Down syndrome and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 12, 219 225.
201. Yoo B. C., Kim S. H., Cairns N. et al. (2001c) Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. Biochem. Biophys. Res. Commun. 280, 249 258. (Pubitemid 32917504)
202. Yu H. L., Chertkow H. M., Bergman H. et al. (2003) Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3, 2240 2248.
203. Zabel C., Andreew A., Mao L. et al. (2008) Protein expression overlap: more important than which proteins change in expression? Expert Rev. Proteomics 5, 187 205.
204. Zellner M., Veitinger M. Umlauf E. (2009) The role of proteomics in dementia and Alzheimer's disease. Acta Neuropathol. 118, 181 195.
205. Zetterberg H., Ruetschi U., Portelius E. et al. (2008) Clinical proteomics in neurodegenerative disorders. Acta Neurol. Scand. 118, 1 11.
206. Zhang R., Barker L., Pinchev D. et al. (2004) Mining biomarkers in human sera using proteomic tools. Proteomics 4, 244 256.
207. Zhang J., Goodlett D. R., Quinn J. F. et al. (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 7, 125 133. discussion 173-180.
208. Zhang J., Sokal I., Peskind E. R. et al. (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129, 526 529.